{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:52:10Z","timestamp":1783021930241,"version":"3.54.6"},"reference-count":39,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.05.052","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T15:12:36Z","timestamp":1685805156000},"page":"4287-4294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity, efficacy, and safety of CoronaVac and Pfizer\/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study"],"prefix":"10.1016","volume":"41","author":[{"given":"Tulin","family":"Ergun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcen","family":"Hosgoren Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Apti Sengun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Akin Cakici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9145-6799","authenticated-orcid":false,"given":"Dilek","family":"Seckin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"Adiay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-5759","authenticated-orcid":false,"given":"Hakan","family":"Enul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goncagul","family":"Haklar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-9298","authenticated-orcid":false,"given":"Uluhan","family":"Sili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2023.05.052_b0005","doi-asserted-by":"crossref","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.vaccine.2023.05.052_b0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10296","key":"10.1016\/j.vaccine.2023.05.052_b0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.05.052_b0020","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2023.05.052_b0025","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2023.05.052_b0030","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.05.052_b0035","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0040","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaad.2020.12.058","article-title":"National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0045","unstructured":"COVID-19 vaccines WHO EUL issued. Available at: https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued."},{"key":"10.1016\/j.vaccine.2023.05.052_b0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.05.052_b0055","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7881","key":"10.1016\/j.vaccine.2023.05.052_b0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China's COVID vaccines have been crucial - now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.05.052_b0065","unstructured":"Republic of Turkey Ministry of Health COVID-19 Vaccination Information Platform. Available at: https:\/\/covid19asi.saglik.gov.tr\/?_Dil=2."},{"key":"10.1016\/j.vaccine.2023.05.052_b0070","unstructured":"World Health Organization COVID-19 Pandemic. Available at: https:\/\/www.who.int."},{"key":"10.1016\/j.vaccine.2023.05.052_b0075","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2023.05.052_b0080","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.3390\/jcm9123989","article-title":"Characterization of a pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study","volume":"9","author":"Schaffner","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.vaccine.2023.05.052_b0085","unstructured":"O'Shaughnessy JA. Convalescent plasma EUA letter of authorization 12282021. Available at: https:\/\/www.fda.gov\/media\/141477\/download."},{"key":"10.1016\/j.vaccine.2023.05.052_b0090","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.05.052_b0095","unstructured":"Investigational COVID-19 convalescent plasma guidance for industry. Available at: https:\/\/www.fda.gov\/media\/136798\/download."},{"key":"10.1016\/j.vaccine.2023.05.052_b0100","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0105","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0110","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","article-title":"Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies","volume":"3","author":"Boekel","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0115","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/ced.15347","article-title":"Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics","volume":"47","author":"Marovt","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0120","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1111\/ced.15395","article-title":"Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics","volume":"47","author":"Megna","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0125","doi-asserted-by":"crossref","first-page":"961904","DOI":"10.3389\/fmed.2022.961904","article-title":"Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics","volume":"9","author":"Graceffa","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.vaccine.2023.05.052_b0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2021.09.055","article-title":"Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"162","author":"Sakuraba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2023.05.052_b0135","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.vaccine.2023.05.052_b0140","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.05.052_b0145","unstructured":"National Psoriasis Foundation. Covid-19 Task Force Guidance Statements. Available at: https:\/\/www.psoriasis.org\/covid-19-task-force-guidance-statements\/."},{"key":"10.1016\/j.vaccine.2023.05.052_b0150","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","article-title":"Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"80","author":"Friedman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2023.05.052_b0155","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","article-title":"Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2023.05.052_b0160","doi-asserted-by":"crossref","unstructured":"Lin S, Kennedy N, Saifuddin A et al. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients; 2021. Doi: 10.21203\/rs.3.rs-755879\/v1.","DOI":"10.21203\/rs.3.rs-755879\/v1"},{"key":"10.1016\/j.vaccine.2023.05.052_b0165","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0170","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.052_b0175","doi-asserted-by":"crossref","first-page":"669010","DOI":"10.3389\/fimmu.2021.669010","article-title":"COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0180","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.05.052_b0185","doi-asserted-by":"crossref","first-page":"e15085","DOI":"10.1111\/dth.15085","article-title":"Onset\/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca\/Covishield): Report of two cases","volume":"34","author":"Nagrani","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.vaccine.2023.05.052_b0190","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/1346-8138.16271","article-title":"Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination","volume":"49","author":"Yatsuzuka","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.vaccine.2023.05.052_b0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.34172\/hpp.2021.32","article-title":"A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report","volume":"11","author":"Onsun","year":"2021","journal-title":"Health Promot Perspect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:51Z","timestamp":1759404471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23006151"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, efficacy, and safety of CoronaVac and Pfizer\/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}